ZYN Gets FDA's Seal of Approval: What the June 2026 Modified Risk Authorization Means

On June 30, 2026, the U.S. Food and Drug Administration issued modified risk granted orders to Swedish Match USA for 20 ZYN nicotine pouches — making ZYN the first nicotine pouch brand in history to receive formal FDA authorization to claim it reduces health risk compared to cigarettes. Here's what that actually means, what the FDA found in its review, and why European buyers should pay attention.

What is an MRTP and Why Is This Historic?

The US tobacco regulatory framework has two key authorization levels. The first is a Premarket Tobacco Product Application (PMTA) — which simply establishes that a product is "appropriate for the protection of public health" and can be legally sold. ZYN cleared this bar in January 2025.

The second level — and far more difficult to achieve — is the Modified Risk Tobacco Product (MRTP) order. This authorizes a company to explicitly claim, in marketing materials, that its product reduces health risk compared to cigarettes. The FDA had never granted an MRTP for a nicotine pouch product before June 30, 2026. For context: conventional cigarette companies have tried and failed to achieve MRTP status for modified-risk cigarette variants for decades. ZYN cleared it.

To obtain an MRTP, Swedish Match USA had to prove three things to the FDA's satisfaction: that the health claim is scientifically accurate, that consumers understand the claim correctly (including its limits — it says "lower risk," not "no risk"), and that marketing the products with the claim would benefit the population as a whole — including accounting for any risk it might pose to non-users or youth who could be drawn in.

The Exact Authorized Claim

The FDA has been specific about what Swedish Match USA may and may not say. The authorized modified risk claim is:

"Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis."

Six specific diseases are named. Each was individually reviewed as part of the scientific evidence package submitted by Swedish Match. The claim is comparative — it positions ZYN against cigarettes — and conditional on the user switching rather than adding ZYN use on top of smoking. The FDA does not say ZYN is safe in absolute terms; it says ZYN is safer than the alternative most likely used by its target consumer.

According to the FDA's official MRTP authorization announcement, the agency also reviewed recommendations from its Tobacco Products Scientific Advisory Committee meeting held January 22, 2026, as well as extensive public comment submissions before reaching its decision.

Which ZYN Products Are Covered?

The authorization covers exactly 20 products: 10 flavours in two strengths each (3mg and 6mg). The 10 flavours are the core ZYN range — Cool Mint, Spearmint, Cinnamon, Citrus, Coffee, Wintergreen, Peppermint, Smooth, Menthol, and Chill. This covers virtually the entire mainstream ZYN lineup available in both the US and European markets.

The authorization is product-specific, not category-wide. Other nicotine pouch brands — VELO, LOOP, XQS — have not received MRTP authorization. Swedish Match/PMI was the first applicant to take this pathway all the way through the US regulatory process for pouches.

What Did the FDA's Review Actually Find?

The scientific review process was extensive, spanning multiple years of submitted data. The FDA evaluated the complete toxicology profile of ZYN products, epidemiological data on oral nicotine use versus smoking, consumer perception studies measuring whether buyers correctly understood the modified risk claim, and population modelling that assessed whether availability of ZYN with risk claims would reduce overall tobacco-related harm or inadvertently encourage new nicotine users.

The conclusion: population-level benefit was positive. This is the hardest part of the MRTP standard to meet. It requires demonstrating that even accounting for people who might start using ZYN who wouldn't otherwise have used any nicotine product, the net health impact across the population is still better with the product available than without it. Swedish Match met this bar.

This aligns with broader scientific consensus on tobacco harm reduction. Research published in Nicotine & Tobacco Research has long established that smokeless nicotine products carry dramatically reduced risk profiles compared to combustible tobacco — ZYN's MRTP authorization puts regulatory weight behind what the science already showed.

Why It Matters for European ZYN Buyers

The EU does not have an MRTP pathway — European tobacco product regulation operates under the Tobacco Products Directive (TPD), not the US framework. So the FDA authorization doesn't change legal status in Europe at all. But it matters for two reasons.

First, the science is the same. ZYN sold in Europe is manufactured by Swedish Match (now a PMI subsidiary) using the same formulations reviewed by the FDA. When the FDA says the modified risk claim for these products is "scientifically accurate," that finding doesn't stop at the US border. The health risk reduction relative to cigarettes applies equally to the European consumer using European ZYN.

Second, it is directly relevant to the EU TPD3 debate. With the European Commission expected to publish a legislative proposal for nicotine pouch regulation in Q4 2026, the FDA's explicit scientific finding that pouches offer a measurable population-level benefit becomes important evidence in the regulatory conversation. Industry bodies and harm reduction advocates across Europe have already begun citing the June 30 authorization in submissions to the Commission.

How ZYN Compares to Other EU Brands on Safety Evidence

Brand	Tobacco-Free	US MRTP Status	EU TPD2 Compliant
ZYN	✅	✅ Granted June 2026	✅
VELO	✅	Not applied / pending	✅
LOOP	✅	Not applied	✅
ZEUS	✅	Not applied	✅
Traditional cigarettes	❌	❌ Never granted	❌ (combustible)

All nicotine pouches are tobacco-free. ZYN is simply the first pouch brand in history to have a major regulatory body formally validate a specific reduced-risk claim through a rigorous scientific review process. The FDA's full MRTP applications record for ZYN is publicly available and runs to thousands of pages of scientific evidence.

FAQ: ZYN FDA MRTP Authorization 2026

Does the FDA authorization make ZYN safe to use?

No — MRTP authorization means the comparative claim is validated. ZYN is authorized to state it poses lower risk than cigarettes. It does not mean ZYN is risk-free. Nicotine is addictive, and the FDA authorization explicitly applies only to current smokers considering a switch.

Does the FDA ruling apply to ZYN sold in Europe?

Not legally — European products are regulated under EU tobacco law, not US FDA law. But the underlying science reviewed by the FDA applies equally to the same ZYN formulations sold in Europe. European buyers can draw confidence from the FDA's scientific conclusion while understanding it carries no formal regulatory status on this side of the Atlantic.

Will other brands like VELO or LOOP get similar FDA authorization?

Neither BAT (VELO) nor other manufacturers have confirmed MRTP applications for European-market pouch brands. The application process is lengthy and expensive. ZYN's success may encourage other major manufacturers to file, but the timeline would be measured in years, not months.

What does this mean for EU TPD3 and possible flavour bans?

The FDA's population-benefit finding strengthens the harm reduction argument against restrictive EU regulation. If the world's most rigorous tobacco regulator has found that ZYN provides net population health benefit — including when all potential risks are modelled — it becomes harder for EU member states to justify prohibition or blanket flavour bans on scientific grounds. The political case remains, but the scientific case has measurably shifted.

Can I buy ZYN in Europe right now?

Yes — ZYN is fully available across EU markets where nicotine pouches are sold legally. The Snus Outlet stocks the full ZYN range, with free EU shipping on orders over €99.

Final Thoughts

The June 30, 2026, FDA MRTP authorization for ZYN is the most significant regulatory milestone in the nicotine pouch category to date. It establishes — through the world's strictest tobacco regulatory process — that switching from cigarettes to ZYN measurably reduces risk for six major diseases. That's not marketing language; it's a regulatory finding backed by thousands of pages of scientific evidence. For current smokers or those weighing nicotine options, the FDA's verdict adds a concrete, independent layer of confidence.

The full ZYN range is available now at The Snus Outlet. Browse ZYN pouches — all strengths, all flavours, free EU shipping on orders over €99.